(firstQuint)Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.

 Capecitabine, oxaliplatin and bevacizumab are well known active agents in the treatment of mCRC.

 The treatment of elderly patients with mCRC is an area of investigation.

 The role of comprehensive geriatric assessment in treatment efficacy and tolerance is an area of investigation.

.

 Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer@highlight

This trial will evaluate the efficacy and safety of the capecitabine and oxaliplatine plus bevacizumab combination as first-line treatment in elderly patients with metastatic colorectal cancer.

